✨ Free AI Report
Ocular Therapeutix, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Ocular Therapeutix, Inc.
Company Research

Ocular Therapeutix, Inc.: Business Overview, Financials & Competitive Analysis

Ocular Therapeutix, Inc. scores 7/10 on the AskCyborg Cyborg Score (Solid). Ocular Therapeutix is a promising ophthalmic biotech with strong late-stage pipeline catalysts and a commercial product, but execution risks and cash burn require careful monitoring. The company has a $1.69B market capitalization with $52M trailing twelve-month revenue. However, the company remains unprofitable with significant cash burn typical of clinical-stage.

What is Ocular Therapeutix, Inc.'s industry? Ocular Therapeutix, Inc. (ocutx.com) operates in Biopharmaceutical - Ophthalmic Therapeutics. AskCyborg classifies Ocular Therapeutix, Inc. under Biopharmaceutical - Ophthalmic Therapeutics in its company registry.

Ocular Therapeutix is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydro...

7/ 10Solid

Cyborg Score thesis

Ocular Therapeutix is a promising ophthalmic biotech with strong late-stage pipeline catalysts and a commercial product, but...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Ophthalmic Therapeutics
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest Ocular Therapeutix, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Ocular Therapeutix, Inc.

AskCyborg analysts argue the bull and bear cases for Ocular Therapeutix, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Ocular Therapeutix, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Ocular Therapeutix, Inc. Overview

Pro stress-test →

Ocular Therapeutix is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology, ELUTYX™. The company markets its FDA-approved product DEXTENZA and has a robust pipeline addressing high-burden ophthalmic conditions including retinal diseases.

Strategic Profile

Pro stress-test →

The company has built a robust product pipeline of drug delivery solutions developed to reduce the complexity and burden of the current standard of care and position itself to become a leader in the ophthalmic space. Its lead program AXPAXLI recently demonstrated positive Phase 3 data for wet AMD, a significant advancement in addressing patient burden from frequent injections.

Competitive Landscape

Pro stress-test →

Ocular Therapeutix competes in the ophthalmic therapeutics space against larger pharmaceutical companies and specialized biotech firms. Competitors include Novo Nordisk, Clearside Biomedical, Sarepta Therapeutics, Mati Therapeutics, and TearClear. The company's differentiated hydrogel platform for sustained drug delivery provides a competitive advantage over traditional eye drop formulations.

Industry Context

Ocular Therapeutix, Inc. operates in Biopharmaceutical - Ophthalmic Therapeutics.

Key facts

Founded: 2006 · Headquarters: Bedford, Massachusetts, US · Employees: 274 · Revenue: $52M · Market cap: $1.69B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Ocular Therapeutix, Inc..

  • AXPAXLI recently demonstrated positive Phase 3 superiority results for wet AMD, potentially addressing major treatment burden from frequent intravitreal injections
  • Proprietary bioresorbable hydrogel platform (ELUTYX) enables sustained delivery across multiple ophthalmic indications reducing patient treatment burden
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • May 2025Reported positive results from landmark SOL-1 Phase 3 superiority trial of AXPAXLI in wet AMD
  • Early 2026Phase 3 SOL-1 clinical trial of AXPAXLI in wet AMD continuing with subjects being screened
  • +1 moreTrack every material event for Ocular Therapeutix, Inc. as it happens. Explore monitoring →
Get alerted when Ocular Therapeutix, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Anti-VEGF TherapiesCurrent standard of care requiring frequent intravitreal injections for wet AMD→Ocular Gene TherapiesCompeting modality for retinal disease treatment→Suprachoroidal DeliveryAlternative drug delivery approach for posterior segment diseases→

Compare Ocular Therapeutix, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Ocular Therapeutix, Inc. operates in Biopharmaceutical - Ophthalmic Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Ophthalmic Therapeutics research →
NEW · MCP server

Ask your AI assistant about Ocular Therapeutix, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Ocular Therapeutix, Inc. and its top competitor on Cyborg Score”
“What did Ocular Therapeutix, Inc. do this quarter?”
“Is Ocular Therapeutix, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Ocular Therapeutix, Inc. do?+
Ocular Therapeutix is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydro...
What is Ocular Therapeutix, Inc.'s Cyborg Score?+
Ocular Therapeutix, Inc. has a Cyborg Score of 7/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Ocular Therapeutix, Inc.'s main competitors?+
Named competitors include Anti-VEGF Therapies, Ocular Gene Therapies, Suprachoroidal Delivery. The full competitive landscape is in the AskCyborg report.
How can I get the full Ocular Therapeutix, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Ocular Therapeutix, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Ocular Therapeutix, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.